198 related articles for article (PubMed ID: 22691057)
1. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).
Scott JS; Bowker SS; Deschoolmeester J; Gerhardt S; Hargreaves D; Kilgour E; Lloyd A; Mayers RM; McCoull W; Newcombe NJ; Ogg D; Packer MJ; Rees A; Revill J; Schofield P; Selmi N; Swales JG; Whittamore PR
J Med Chem; 2012 Jun; 55(12):5951-64. PubMed ID: 22691057
[TBL] [Abstract][Full Text] [Related]
2. Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).
Scott JS; deSchoolmeester J; Kilgour E; Mayers RM; Packer MJ; Hargreaves D; Gerhardt S; Ogg DJ; Rees A; Selmi N; Stocker A; Swales JG; Whittamore PR
J Med Chem; 2012 Nov; 55(22):10136-47. PubMed ID: 23088558
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
[TBL] [Abstract][Full Text] [Related]
4. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).
Véniant MM; Hale C; Hungate RW; Gahm K; Emery MG; Jona J; Joseph S; Adams J; Hague A; Moniz G; Zhang J; Bartberger MD; Li V; Syed R; Jordan S; Komorowski R; Chen MM; Cupples R; Kim KW; St Jean DJ; Johansson L; Henriksson MA; Williams M; Vallgårda J; Fotsch C; Wang M
J Med Chem; 2010 Jun; 53(11):4481-7. PubMed ID: 20465278
[TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
7. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Xia G; You X; Liu L; Liu H; Wang J; Shi Y; Li P; Xiong B; Liu X; Shen J
Eur J Med Chem; 2013 Apr; 62():1-10. PubMed ID: 23353742
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.
Tice CM; Zhao W; Krosky PM; Kruk BA; Berbaum J; Johnson JA; Bukhtiyarov Y; Panemangalore R; Scott BB; Zhao Y; Bruno JG; Howard L; Togias J; Ye YJ; Singh SB; McKeever BM; Lindblom PR; Guo J; Guo R; Nar H; Schuler-Metz A; Gregg RE; Leftheris K; Harrison RK; McGeehan GM; Zhuang L; Claremon DA
Bioorg Med Chem Lett; 2010 Nov; 20(22):6725-9. PubMed ID: 20864344
[TBL] [Abstract][Full Text] [Related]
11. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
13. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1.
Xia G; Liu L; Xue M; Liu H; Yu J; Li P; Chen Q; Xiong B; Liu X; Shen J
Mol Cell Endocrinol; 2012 Jul; 358(1):46-52. PubMed ID: 22410288
[TBL] [Abstract][Full Text] [Related]
17. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
18. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Ganeshapillai D; Smith A; Purohit A; Reed MJ; Potter BV
Mol Cell Endocrinol; 2006 Mar; 248(1-2):214-7. PubMed ID: 16325333
[TBL] [Abstract][Full Text] [Related]
19. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
